Action ELAB ELEVAI LABS INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Elevai Labs Inc.

Actions

ELAB

US28622K1043

Marché Fermé - Nasdaq
Autres places de cotation
 22:30:00 17/05/2024 		Varia. 5j. Varia. 1 janv.
0,6851 USD +5,38 % Graphique intraday de Elevai Labs Inc. +5,40 % -62,53 %
02/05 Elevai Biosciences Inc. présente les données précliniques montrant le potentiel de son actif sous licence " EL-22 " pour le traitement de l'obésité CI
01/05 Elevai Labs s'agrandit avec le lancement des filiales Elevai Biosciences et Elevai Skincare CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Elevai Labs Inc. Reports First Quarter 2024 Financial Results
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
Elevai Biosciences Inc. Highlights Preclinical Data Showing Potential of In-Licensed Asset ?EL-22? for The Treatment of Obesity
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries
Elevai Labs Inc. Announces Executive Changes
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Elevai Labs Enters into Exclusive Licensing Agreement with MOA Life Plus Co., Ltd to Develop and Commercialize Two Novel Assets for the Treatment of Obesity and Muscle Loss Prevention
Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments
Elevai Labs Signs Exclusive Distribution Deal for Taiwan
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
Elevai Labs, Inc. Enters the Taiwan Market with Signing of 5Th International Distribution Agreement in 14 Months
Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results
Elevai Labs, Inc. Launches E-Commerce Portal
Elevai Labs, Inc. Announces Board Changes
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach
ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ELAB
  4. Actualités Elevai Labs Inc.
  5. Autres langues